EUROAPI Engages with French Ministers to Enhance Healthcare Solutions
EUROAPI recently had the honor of hosting the French Minister for Health and Access to Healthcare as well as the Minister for Industry and Energy, demonstrating the company's dedication to the future of pharmaceutical development. This visit took place at the company’s industrial site in Vertolaye, where the ministers were able to see firsthand the extensive capabilities and operations of the plant.
A Commitment to Health Sovereignty
During this important visit, EUROAPI showcased its long-standing commitment to health sovereignty, a concept that emphasizes the importance of maintaining control over domestic pharmaceutical production for better healthcare access. The Vertolaye site, renowned for its specialization in corticosteroids, produces essential active ingredients crucial for treating various inflammatory and immune conditions. The visit underscored the strategic importance of this facility in supporting both national and European healthcare objectives.
Insights from Company Leadership
David Seignolle, the Chief Executive Officer of EUROAPI, expressed the significance of the ministers' visit. He conveyed appreciation for their ongoing support of the pharmaceutical sector, remarking, “The Vertolaye site has a rich heritage combining industrial performance and environmental responsibility. Our dedicated future projects aim to enhance our site’s competitiveness sustainably, ultimately benefiting patients across France and Europe.”
Focusing on Innovative Technologies
The Vertolaye facility not only focuses on corticosteroids but also houses a major development center that plays a critical role in the Important Project of Common European Interest (IPCEI) related to the pharmaceutical industry. This project seeks to foster innovation and research within the sector. A few key areas of development include:
- Advancing corticosteroid production processes to deliver state-of-the-art treatment options like methylprednisolone.
- Exploring nanoparticles to boost the bioavailability of therapeutic molecules, thereby expanding their potential applications across existing and new pharmaceutical formulations.
EUROAPI’s Legacy and Global Reach
Established in the Puy-de-Dôme region since 1939, EUROAPI has significantly contributed to the healthcare landscape by employing a diverse workforce of approximately 700 individuals. The plant efficiently produces over 65 active pharmaceutical ingredients, catering to the needs of more than 300 customers across 60 countries. This global outreach showcases the company's capability and commitment to quality, as evidenced by its certifications from both national and international health authorities, including the ANSM in France and the FDA in the United States.
Environmental and Quality Certifications
In addition to regulatory approvals, the Vertolaye plant holds prestigious ISO certifications in environmental and energy management (ISO 14001 and ISO 50001 respectively), highlighting its dedication to sustainable operational practices.
About EUROAPI
As a key player in manufacturing active pharmaceutical ingredients, EUROAPI is dedicated to innovating solutions that meet the evolving demands of healthcare. With a product portfolio comprising around 200 items, the company is strategically positioned to engage in the development of new and improved molecules through its Contract Development and Manufacturing Organization (CDMO) services.
Each day, the enthusiastic team of around 3,650 professionals at EUROAPI draws inspiration from their mission of ensuring access to essential therapies across the globe. With six manufacturing facilities located throughout Europe, the company guarantees top-notch production standards, aiming to support customers spanning over 80 nations.
Frequently Asked Questions
What was the purpose of the ministers' visit to EUROAPI?
The visit aimed to showcase EUROAPI’s commitment to health sovereignty and its advanced pharmaceutical production capabilities, primarily focusing on corticosteroids.
How does EUROAPI support health sovereignty?
EUROAPI emphasizes maintaining control over domestic pharmaceutical production to ensure better healthcare access, thereby guaranteeing essential therapies for patients.
What are some key areas of research at the Vertolaye plant?
The plant focuses on advancing corticosteroid production and exploring nanoparticle applications to enhance the bioavailability of certain therapeutic drugs.
What certifications does the Vertolaye facility hold?
The facility is certified by numerous health authorities and holds ISO 14001 and ISO 50001 certifications for its environmental and energy performance.
How many employees does EUROAPI have?
EUROAPI employs approximately 3,650 professionals across its six manufacturing sites, all dedicated to delivering high-quality pharmaceutical ingredients.
